the importance of myeloma-specific frailty indices in trial design
Published 11 hours ago • 12 plays • Length 1:23Download video MP4
Download video MP3
Similar videos
-
0:52
the importance of incorporating frailty assessment tools in clinical practice for multiple myeloma
-
3:06
the imwg frailty score explained
-
2:31
the future of multiple myeloma treatment: genetic tests and frailty
-
1:53
the future of multiple myeloma treatment
-
4:45
a first-in-human trial of linvoseltamab (regn5458) in r/r myeloma: updated phase i data
-
1:47
the role of precursor conditions in myeloma
-
2:06
the importance of proteomic analysis in myeloma and future outlooks
-
1:08
outcomes of patients with triple-class refractory myeloma: a single-center retrospective study
-
6:23
results of maintenance therapy in high-risk myeloma patients | ajay nooka, md, mph, facp | asco 2023
-
2:57
linker-mm1: promising safety and efficacy of linvoseltamab in r/r multiple myeloma
-
5:22
individualized prediction model in myeloma & genome sequencing | francesco maura, md | ash 2022
-
2:54
what is the future for myeloma clinical trials?
-
1:26
insight-mm study update: treatment patterns in first and second-line multiple myeloma
-
3:17
pre-mds states: novel therapeutic approaches, and determining appropriate trial endpoints
-
1:54
the future of multiple myeloma treatment
-
0:52
novel strategies to evaluate biomarkers of interest in multiple myeloma
-
4:48
unmet needs in unfit/frail patients with multiple myeloma
-
1:25
the importance of identifying and understanding high-risk multiple myeloma
-
1:33
outcomes of reduced intensity allosct in patients with accelerated-phase myelofibrosis
-
2:31
defining precursor conditions in multiple myeloma & strategies to better predict risk of progression
-
2:41
an overview of the latest advances in hematology
-
2:11
future myeloma treatment strategies